# Assura PLC (AGR.L): A Closer Look at the UK’s Leading Healthcare REIT and Its Investment Potential

- Link: https://www.directorstalkinterviews.com/assura-plc-agr-l-a-closer-look-at-the-uks-leading-healthcare-reit-and-its-investment-potential/4121213540
- Published: 2025-08-26T04:04:25+01:00
- Author: Katherine Hargreaves

Assura PLC (AGR.L), a prominent name in the real estate sector, stands as the UK’s
leading diversified healthcare Real Estate Investment Trust (REIT). Based in Altrincham,
Assura’s commitment to enhancing health outcomes is evident through its extensive
portfolio of more than 600 healthcare facilities, serving over six million patients.
As a constituent of the [FTSE 250](https://www.directorstalkinterviews.com/news/ftse-250)
and the EPRA indices, alongside a secondary listing on the Johannesburg Stock Exchange,
Assura plays a pivotal role in the healthcare infrastructure landscape.

With a market capitalisation of $1.58 billion, Assura has positioned itself as a
significant player within the healthcare facilities industry. Currently trading 
at 48.68 GBp, the stock’s 52-week range reflects resilience, having fluctuated between
35.34 GBp and 50.65 GBp. Investors might find the stability in its price particularly
appealing, given the modest 0.14 GBp (0.00%) change.

Valuation metrics present an intriguing picture, with a forward P/E ratio of 1,323.19,
which might raise eyebrows. This figure suggests that investors are paying a premium
for anticipated future earnings, indicative of the market’s confidence in Assura’s
long-term growth potential. However, the absence of trailing P/E, PEG, and other
conventional valuation metrics might require investors to delve deeper into qualitative
assessments.

From a financial performance perspective, Assura boasts a commendable revenue growth
of 24.30%, complemented by an earnings per share (EPS) of 0.05 and a return on equity(
ROE) of 10.66%. These metrics reflect a robust operational framework. Moreover, 
the company’s free cash flow stands at a substantial £57.26 million, underscoring
liquidity and financial flexibility to support growth initiatives and shareholder
returns.

Dividend-seeking investors might find Assura’s yield of 6.90% particularly attractive,
supported by a payout ratio of 63.40%. This suggests a sustainable dividend policy,
balancing reward to shareholders with reinvestment for future expansion.

Analyst sentiment towards Assura is cautiously optimistic, with two buy ratings 
and three hold ratings. The target price range of 48.00 GBp to 60.00 GBp, with an
average target of 52.25 GBp, indicates a potential upside of 7.33%. This presents
a favourable outlook for those considering an entry point at current price levels.

Technically, the stock’s 50-day moving average of 49.68 GBp and 200-day moving average
of 44.55 GBp highlight a near-term consolidation phase, while the RSI (14) of 49.17
suggests the stock is neither overbought nor oversold. The MACD at -0.42 and signal
line at -0.40 imply a neutral to slight bearish momentum, warranting close monitoring
for trend changes.

Assura’s commitment to environmental, social, and governance (ESG) principles, as
the first FTSE 250 certified B Corp, further enhances its appeal to socially conscious
investors. The company’s strategy to create healthy environments and communities
aligns well with the growing investor demand for sustainable and ethical investment
opportunities.

With a portfolio valued at £3.1 billion as of March 2025, Assura’s strong track 
record of financial returns and dividend growth positions it as a compelling investment
within the healthcare REIT sector. For investors seeking exposure to a stable, yield-
generating asset underpinned by a robust healthcare infrastructure, Assura PLC offers
a noteworthy proposition worth considering.

Share on: